Enrolling by invitationEarly Phase 1NCT06565572
Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1
Studying Posterior column ataxia-retinitis pigmentosa syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Colorado, Denver
- Intervention
- nL-FLVC-001(drug)
- Enrollment
- 1 enrolled
- Eligibility
- All sexes
- Timeline
- 2023 – 2028
Study locations (1)
- Childrens Hospital Colorado, Aurora, Colorado, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06565572 on ClinicalTrials.gov